TY - JOUR AU - Girard, N. PY - 2014 DA - 2014// TI - Thymic tumors: adopting an orphan thoracic tumor as a model of personalized medicine JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000392 DO - 10.1097/JTO.0000000000000392 ID - Girard2014 ER - TY - JOUR AU - Marx, A. AU - Strobel, P. AU - Badve, S. S. AU - Chalabreysse, L. AU - Chan, J. K. AU - Chen, G. PY - 2014 DA - 2014// TI - ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000154 DO - 10.1097/JTO.0000000000000154 ID - Marx2014 ER - TY - JOUR AU - Girard, N. PY - 2012 DA - 2012// TI - Chemotherapy and targeted agents for thymic malignancies JO - Expert Rev Anticancer Ther VL - 12 UR - https://doi.org/10.1586/era.12.29 DO - 10.1586/era.12.29 ID - Girard2012 ER - TY - JOUR AU - Remon, J. AU - Girard, N. AU - Mazieres, J. AU - Dansin, E. AU - Pichon, E. AU - Greillier, L. PY - 2016 DA - 2016// TI - Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network JO - Lung Cancer VL - 97 UR - https://doi.org/10.1016/j.lungcan.2016.04.024 DO - 10.1016/j.lungcan.2016.04.024 ID - Remon2016 ER - TY - JOUR AU - Giaccone, G. AU - Rajan, A. AU - Ruijter, R. AU - Smit, E. AU - Groeningen, C. AU - Hogendoorn, P. C. PY - 2009 DA - 2009// TI - Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas JO - J Thorac Oncol VL - 4 UR - https://doi.org/10.1097/JTO.0b013e3181b6be57 DO - 10.1097/JTO.0b013e3181b6be57 ID - Giaccone2009 ER - TY - JOUR AU - Wheler, J. AU - Hong, D. AU - Swisher, S. G. AU - Falchook, G. AU - Tsimberidou, A. M. AU - Helgason, T. PY - 2013 DA - 2013// TI - Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses JO - Oncotarget VL - 4 UR - https://doi.org/10.18632/oncotarget.1015 DO - 10.18632/oncotarget.1015 ID - Wheler2013 ER - TY - JOUR AU - Guibert, N. AU - Delaunay, M. AU - Mazieres, J. PY - 2015 DA - 2015// TI - Targeting the immune system to treat lung cancer: rationale and clinical experience JO - Ther Adv Respir Dis VL - 9 UR - https://doi.org/10.1177/1753465815578349 DO - 10.1177/1753465815578349 ID - Guibert2015 ER - TY - JOUR AU - Fehrenbacher, L. AU - Spira, A. AU - Ballinger, M. AU - Kowanetz, M. AU - Vansteenkiste, J. AU - Mazieres, J. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00587-0 DO - 10.1016/S0140-6736(16)00587-0 ID - Fehrenbacher2016 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Giaccone, G. AU - Kim, C. AU - Thompson, J. AU - McGuire, C. AU - Kallakury, B. AU - Chahine, J. J. PY - 2018 DA - 2018// TI - Pembrolizumab in patients with thymic carcinoma: a single-arm, single-Centre, phase 2 study JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30062-7 DO - 10.1016/S1470-2045(18)30062-7 ID - Giaccone2018 ER - TY - JOUR AU - Padda, S. K. AU - Riess, J. W. AU - Schwartz, E. J. AU - Tian, L. AU - Kohrt, H. E. AU - Neal, J. W. PY - 2015 DA - 2015// TI - Diffuse high intensity PD-L1 staining in thymic epithelial tumors JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000429 DO - 10.1097/JTO.0000000000000429 ID - Padda2015 ER - TY - JOUR AU - Yokoyama, S. AU - Miyoshi, H. AU - Nishi, T. AU - Hashiguchi, T. AU - Mitsuoka, M. AU - Takamori, S. PY - 2016 DA - 2016// TI - Clinicopathologic and prognostic implications of programmed death ligand 1 expression in Thymoma JO - Ann Thorac Surg VL - 101 UR - https://doi.org/10.1016/j.athoracsur.2015.10.044 DO - 10.1016/j.athoracsur.2015.10.044 ID - Yokoyama2016 ER - TY - JOUR AU - Katsuya, Y. AU - Fujita, Y. AU - Horinouchi, H. AU - Ohe, Y. AU - Watanabe, S. AU - Tsuta, K. PY - 2015 DA - 2015// TI - Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma JO - Lung Cancer VL - 88 UR - https://doi.org/10.1016/j.lungcan.2015.03.003 DO - 10.1016/j.lungcan.2015.03.003 ID - Katsuya2015 ER - TY - JOUR AU - Chalabreysse, L. PY - 2014 DA - 2014// TI - Thomas De Montpreville V, De Muret a, Hofman V, Lantuejoul S, Parrens M, et al. [Rythmic-pathology: the French national pathology network for thymic epithelial tumours] JO - Ann Pathol VL - 34 UR - https://doi.org/10.1016/j.annpat.2014.01.010 DO - 10.1016/j.annpat.2014.01.010 ID - Chalabreysse2014 ER - TY - JOUR AU - Marx, A. AU - Chan, J. K. AU - Coindre, J. M. AU - Detterbeck, F. AU - Girard, N. AU - Harris, N. L. PY - 2015 DA - 2015// TI - The 2015 World Health Organization classification of tumors of the Thymus: continuity and changes JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000654 DO - 10.1097/JTO.0000000000000654 ID - Marx2015 ER - TY - JOUR AU - Weissferdt, A. AU - Fujimoto, J. AU - Kalhor, N. AU - Rodriguez, J. AU - Bassett, R. AU - Wistuba, I. I. PY - 2017 DA - 2017// TI - Expression of PD-1 and PD-L1 in thymic epithelial neoplasms JO - Mod Pathol VL - 30 UR - https://doi.org/10.1038/modpathol.2017.6 DO - 10.1038/modpathol.2017.6 ID - Weissferdt2017 ER - TY - JOUR AU - Marchevsky, A. M. AU - Walts, A. E. PY - 2017 DA - 2017// TI - PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus JO - Hum Pathol VL - 60 UR - https://doi.org/10.1016/j.humpath.2016.09.023 DO - 10.1016/j.humpath.2016.09.023 ID - Marchevsky2017 ER - TY - JOUR AU - Owen, D. AU - Chu, B. AU - Lehman, A. M. AU - Annamalai, L. AU - Yearley, J. H. AU - Shilo, K. PY - 2018 DA - 2018// TI - Expression patterns, prognostic value, and Intratumoral heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic carcinoma JO - J Thorac Oncol VL - 13 UR - https://doi.org/10.1016/j.jtho.2018.04.013 DO - 10.1016/j.jtho.2018.04.013 ID - Owen2018 ER - TY - JOUR AU - Wei, Y. F. AU - Chu, C. Y. AU - Chang, C. C. AU - Lin, S. H. AU - Su, W. C. AU - Tseng, Y. L. PY - 2018 DA - 2018// TI - Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma JO - Lung Cancer VL - 125 UR - https://doi.org/10.1016/j.lungcan.2018.09.002 DO - 10.1016/j.lungcan.2018.09.002 ID - Wei2018 ER - TY - JOUR AU - Hakiri, S. AU - Fukui, T. AU - Mori, S. AU - Kawaguchi, K. AU - Nakamura, S. AU - Ozeki, N. PY - 2019 DA - 2019// TI - Clinicopathologic features of Thymoma with the expression of programmed death ligand 1 JO - Ann Thorac Surg VL - 107 UR - https://doi.org/10.1016/j.athoracsur.2018.08.037 DO - 10.1016/j.athoracsur.2018.08.037 ID - Hakiri2019 ER - TY - JOUR AU - Duan, J. AU - Liu, X. AU - Chen, H. AU - Sun, Y. AU - Liu, Y. AU - Bai, H. PY - 2018 DA - 2018// TI - Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8(+) T cells on clinical outcome of patients with advanced thymic epithelial tumors JO - Thorac Cancer VL - 9 UR - https://doi.org/10.1111/1759-7714.12826 DO - 10.1111/1759-7714.12826 ID - Duan2018 ER - TY - JOUR AU - Herbst, R. S. AU - Baas, P. AU - Kim, D. W. AU - Felip, E. AU - Perez-Gracia, J. L. AU - Han, J. Y. PY - 2016 DA - 2016// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2016 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Inoue, M. AU - Starostik, P. AU - Zettl, A. AU - Strobel, P. AU - Schwarz, S. AU - Scaravilli, F. PY - 2003 DA - 2003// TI - Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas JO - Cancer Res VL - 63 ID - Inoue2003 ER - TY - JOUR AU - Wang, X. AU - Li, M. PY - 2019 DA - 2019// TI - Correlate tumor mutation burden with immune signatures in human cancers JO - BMC Immunol VL - 20 UR - https://doi.org/10.1186/s12865-018-0285-5 DO - 10.1186/s12865-018-0285-5 ID - Wang2019 ER - TY - JOUR AU - Yu, L. AU - Ke, J. AU - Du, X. AU - Yu, Z. AU - Gao, D. PY - 2019 DA - 2019// TI - Genetic characterization of thymoma JO - Sci Rep VL - 9 UR - https://doi.org/10.1038/s41598-019-38878-z DO - 10.1038/s41598-019-38878-z ID - Yu2019 ER - TY - JOUR AU - Cho, J. AU - Kim, H. S. AU - Ku, B. M. AU - Choi, Y. L. AU - Cristescu, R. AU - Han, J. PY - 2019 DA - 2019// TI - Pembrolizumab for patients with refractory or relapsed Thymic epithelial tumor: an open-label phase II trial JO - J Clin Oncol VL - 37 UR - https://doi.org/10.1200/JCO.2017.77.3184 DO - 10.1200/JCO.2017.77.3184 ID - Cho2019 ER - TY - JOUR AU - Giaccone, G. AU - Thompson, J. AU - McGuire, C. AU - Manning, M. AU - Kallakury, B. AU - Chahine, J. J. PY - 2017 DA - 2017// TI - Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.8573 DO - 10.1200/JCO.2017.35.15_suppl.8573 ID - Giaccone2017 ER -